SCHEDULE: Vanguard Boosts Zoetis Stake to 10.84%

The Vanguard Group reported an increased beneficial ownership of 10.84% in Zoetis Inc., holding 47,778,909 shares as of December 31, 2025.

Summary

• The Vanguard Group, an investment adviser, reported beneficial ownership of 47,778,909 shares of Zoetis Inc. common stock.
• This represents 10.84% of Zoetis Inc.'s outstanding common stock.
• Vanguard holds sole dispositive power over 43,395,509 shares and shared dispositive power over 4,383,400 shares.
• Shared voting power is held over 2,768,187 shares, with no sole voting power.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Zoetis Inc.

Sentiment

Score: 7

Explanation: The filing indicates a significant and stable institutional investment by The Vanguard Group in Zoetis Inc., suggesting confidence in the company's long-term value. While not a performance report, a large passive stake from a reputable fund manager is generally viewed positively by the market.

Positives

• A significant stake (10.84%) held by a major institutional investor like Vanguard can signal long-term confidence in Zoetis Inc.'s business fundamentals and future prospects.
• Vanguard's certification that the shares are held in the ordinary course of business and not for control purposes suggests a passive, investment-oriented position.

Industry Context

The disclosure of a major institutional investor like The Vanguard Group holding a significant stake in Zoetis Inc. reinforces the company's position as an attractive investment within the animal health and pharmaceutical sector. Large, passive institutional holdings are common for established companies in stable industries, indicating broad market confidence.

Stakeholder Impact

• Shareholders: The significant stake held by Vanguard may provide a sense of stability and institutional backing, potentially attracting other investors.
• Management: A large, passive institutional investor typically encourages sound corporate governance and long-term strategic planning.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a disclosure of beneficial ownership by a major institutional investor, The Vanguard Group. It indicates a significant, passive stake in Zoetis Inc., reflecting Vanguard's long-term investment strategy rather than a change in the company's operational or financial performance. As such, the filing itself does not provide new information warranting a 'buy' or 'sell' recommendation, but rather reinforces a 'hold' position for investors who value institutional confidence and stability.

Keywords

Zoetis Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Animal Health, Pharmaceuticals